# ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection

> **NCT03183128** · PHASE3 · COMPLETED · sponsor: **Seres Therapeutics, Inc.** · enrollment: 182 (actual)

## Conditions studied

- Clostridium Difficile Infection

## Interventions

- **BIOLOGICAL:** SER-109
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03183128
- **Lead sponsor:** Seres Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-10
- **Primary completion:** 2020-07-03
- **Final completion:** 2020-09-29
- **Target enrollment:** 182 (ACTUAL)
- **Last updated:** 2023-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03183128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03183128, "ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03183128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*